Endocrinology Search
Endocrinology Endocrinology
infertility
INFERTILITY

Infertility is when a couple of reproductive age is unable to conceive after a year or more of regular unprotected intercourse.

It can be primary if no pregnancy has ever occurred or secondary if pregnancy has occurred irrespective of the outcome.

Ovulation induction is part of the patient's management which aims to achieve development of a single follicle and subsequent ovulation in a woman with anovulation.

Drug Information

Dosage: Dysmenorrhoea 10 mg bd from day 5-25 of the cycle. Endometriosis 10 mg bd-tds from day 5-25 of the cycle or co

Indication: Parkinson's disease. Menstrual disorders & infertility. Benign breast disease. Prolactinoma. Acromegaly.

Indication: Controlled ovarian stimulation (COS) in combination w/ a GnRH antagonist for the development of multiple folli...

Dosage:  Hormone replacement therapy for women w/ disorders due to natural or surgically induced menopause w/ intact u

Indication: Puregon Vial/Cartridge Women: Anovulation in women who have been unresponsive to treatment w/ clomiphene ...

Indication: Prevention of premature ovulation in patients undergoing a controlled ovarian stimulation followed by oocyte p...

Indication: Induction of ovulation in patients w/ persistent ovulatory dysfunction as the cause of infertility.

Indication: Disorders associated w/ progesterone deficiency eg, infertility due to inadequate luteal phase; for use during...

Indication: Premenstrual syndrome (PMS) including premenstrual tension & depression. Luteal phase support as part of a...

Indication: Locally advanced or metastatic prostate cancer. Genital & extragenital stage I-IV endometriosis. Precociou...

1  /  4
1  /  4
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Newly approved oral anti-diabetic medication now available in Malaysia
Hannah Wong, 30 Sep 2019

Taisho Pharmaceutical launches Lusefi®, an oral anti-diabetic medication for type 2 diabetes mellitus (T2DM). The medication is expected to lower blood glucose and provide adequate glycaemic control, serving as a new alternative prescription for T2DM. Lusefi, with its active ingredient luseogliflozin hydrate, is available in the form of 2.5 mg and 5 mg tablets.
DIABESITY AND THE ROLE OF DIABETIC-SPECIFIC FORMULA IN IMPROVING DIABETES AND OBESITY OUTCOMES
02 May 2019
At a recent Abbott lunch symposium held in conjunction with the joint 12th International Diabetes FederationWestern Pacific Region Congress & 10th Asian Association for the Study of Diabetes Scientific Meeting in KualaLumpur, Professor Shashank R. Joshi extensively discussed the issue of diabetes in obesity and the role of nutritionalintervention in addressing this growing problem.
Dapagliflozin slows eGFR decline in diabetics
Tristan Manalac, 19 Nov 2019
Dapagliflozin is able to delay renal disease progression among patients with type 2 diabetes, even in those with normal kidney function, according to a study presented at the recently concluded Kidney Week 2019 of the American Society of Nephrology (ASN 2019).
Diabetes mellitus negatively influences pancreatic cancer outcomes
07 Oct 2019
In pancreatic cancer patients undergoing chemotherapy, the presence of diabetes mellitus is associated with reduced survival and larger tumour, as well as with increased risk of death after treatment, according to a meta-analysis.